Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis

• Published in: European Respiratory Journal Vol. 56; no. 4; p. 2002554
• Main Authors: Armstrong-James, Darius, Youngs, Jonathan, Bicanic, Tihana, Abdolrasouli, Alireza, Denning, David W, Johnson, Elizabeth, Mehra, Varun, Pagliuca, Tony, Patel, Brijesh, Rhodes, Johanna, Schelenz, Silke, Shah, Anand, van de Veerdonk, Frank L, Verweij, Paul E, White, P Lewis, Fisher, Matthew C
• Format: Journal Article Web Resource
• Language: English
• Published: England European Respiratory Society Journals Ltd 01.10.2020; European Respiratory Society
• Subjects: Adrenal Cortex Hormones - therapeutic use; Antifungal Agents - therapeutic use; Betacoronavirus; Bronchoalveolar Lavage Fluid - microbiology; Bronchoscopy; Coinfection - diagnosis; Coinfection - drug therapy; Coinfection - epidemiology; Coronavirus Infections - drug therapy; Coronavirus Infections - epidemiology; COVID-19; COVID-19 Drug Treatment; Humans; Immunologic Factors - therapeutic use; Intensive Care Units; Invasive Pulmonary Aspergillosis - diagnosis; Invasive Pulmonary Aspergillosis - drug therapy; Invasive Pulmonary Aspergillosis - epidemiology; Pandemics; Pneumonia, Viral - drug therapy; Pneumonia, Viral - epidemiology; Pulmonary Aspergillosis - diagnosis; Pulmonary Aspergillosis - drug therapy; Pulmonary Aspergillosis - epidemiology; Risk Factors; SARS-CoV-2; Ventilation
• ISSN: 0903-1936; 1399-3003
• DOI: 10.1183/13993003.02554-2020

Cases of COVID-19 associated pulmonary aspergillosis (CAPA) are being increasingly reported and physicians treating patients with COVID-19-related lung disease need to actively consider these fungal co-infections.